More than 80% complete remission rate in Novartis' CAR-T therapy trial

6 December 2016
2019_biotech_test_vial_discovery_big

Novartis (NOVN: VX) has described the findings of its trial of CTL019 in children and young adults with relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (ALL) as a sign of “exciting progress.”

The Swiss pharma giant has presented results from its ELIANA trial evaluating the efficacy and safety of this investigational chimeric antigen receptor T cell (CAR-T) therapy at the 8th American Society of Hematology (ASH) annual meeting.

"This first-of-its-kind trial represents exciting progress toward our goal of helping children and young adults with relapsed or refractory B-cell ALL, a patient population with an urgent need for new treatment options"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology